|Articles|July 28, 2009
Retina Roundtable Session 3
Advertisement
Subscribe
In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.
Participants include:
Return to
Return to
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement